According to the company, this once-daily oral medication, available in 40mg and 80mg tablets, is the first new treatment option for hyperuricemia in patients with gout in more than 40 years.
Uloric was discovered by Teijin Pharma and licensed to Takeda for the US market.
Uloric was studied and evaluated in multiple clinical trials involving more than 4,000 subjects, in some for up to five years. The pivotal, Phase III clinical trial, Confirms, demonstrated that Uloric 80mg was superior to Uloric 40mg and allopurinol 300/200mg (67%, 45% and 42%, respectively) at achieving serum uric acid levels of less than 6mg/dl at the final visit (both p<0.001).